Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27FO6 |
Molecular Weight | 394.4339 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
InChI
InChIKey=GFNANZIMVAIWHM-OBYCQNJPSA-N
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
Molecular Formula | C21H27FO6 |
Molecular Weight | 394.4339 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19744340 |
1.5 nM [IC50] | ||
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D00984 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date1957 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7202 ng/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1911 ng × h/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.7 day |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
120 mg 1 times / day multiple, intramuscular Higher than recommended Dose: 120 mg, 1 times / day Route: intramuscular Route: multiple Dose: 120 mg, 1 times / day Sources: |
unhealthy, 28-57 |
|
360 mg single, intramuscular Highest studied dose Dose: 360 mg Route: intramuscular Route: single Dose: 360 mg Sources: |
unhealthy, 37.5 |
|
200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: |
unhealthy, 46 |
Disc. AE: Cushing's syndrome... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cushing's syndrome | Disc. AE | 200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: |
unhealthy, 46 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10570047/ |
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. Page: 10.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Symptomatic spinal epidural lipomatosis after local epidural corticosteroid injections: case report. | 1999 Jul |
|
Cutaneous drug reaction case reports: from the world literature. | 2001 |
|
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease? | 2001 |
|
Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. | 2001 Apr |
|
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists. | 2001 Aug |
|
Transforming growth factor beta2 induced pleurodesis is not inhibited by corticosteroids. | 2001 Aug |
|
Pericardial access using the PerDUCER and flexible percutaneous pericardioscopy. | 2001 Dec 1 |
|
Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. | 2001 Feb |
|
Facial tumescent solution for cryosurgery: subtract the epinephrine, add a steroid, and avoid spinal needles. | 2001 Jan |
|
In vitro and in vivo techniques used in drug development for evaluation of dose delivery of inhaled corticosteroids. | 2001 Jan |
|
Orofacial granulomatosis with gingival onset. | 2001 Jul |
|
Necrobiosis lipoidica in a 9-year-old girl with new-onset type II diabetes mellitus. | 2001 Jul-Aug |
|
A minimally invasive approach for treating postoperative seromas after incisional hernia repair. | 2001 Jul-Sep |
|
Tonsillar fossa steroid injection for reduction of the post-tonsillectomy pain. | 2001 Jun |
|
Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. | 2001 Jun |
|
Ultrasound guided injection of plantar fasciitis. | 2001 Jun |
|
Lesson of the week: Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. | 2001 Jun 30 |
|
Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. | 2001 Mar |
|
Steroid injection and splinting in the treatment of carpal tunnel syndrome. | 2001 May |
|
Inhaled triamcinolone and chronic obstructive pulmonary disease. | 2001 May 17 |
|
Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. | 2001 May 23-30 |
|
Plasma cell mucositis. | 2001 Nov |
|
Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice. | 2001 Nov |
|
Apoptosis of airway epithelial cells induced by corticosteroids. | 2001 Nov 15 |
|
Safety of steroid injections in the treatment of nasofrontal recess obstruction. | 2001 Nov-Dec |
|
Two cases of morphea associated with Hashimoto's thyroiditis. | 2002 |
|
Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients. | 2002 Apr |
|
[The effect of triamcinolone acetonide, montelukast, nedocromil sodium, formoterol on levels levels of sICAM-1, sIL-2R in serum and clinical course of asthma in children]. | 2002 Feb |
|
A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. | 2002 Feb |
|
Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone. | 2002 Jan-Feb |
|
Salmeterol was not as effective as triamcinolone for persistent asthma. | 2002 Jan-Feb |
|
Correction of the soft tissue pollybeak using triamcinolone injection. | 2002 Jan-Mar |
|
Intravitreal triamcinolone in recurrence of choroidal neovascularisation. | 2002 Jun |
|
Spontaneous bleeding following steroid injection and silicone-gel sheeting in a keloid scar. | 2002 Mar |
|
CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. | 2002 May |
|
Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. | 2002 May |
|
Local injection treatment for lateral epicondylitis. | 2002 May |
|
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. | 2002 May |
Sample Use Guides
The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14406639
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:26:21 GMT 2025
by
admin
on
Mon Mar 31 21:26:21 GMT 2025
|
Record UNII |
1ZK20VI6TY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QH02AB08
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QA01AC01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07BB03
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
LIVERTOX |
994
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
R03BA06
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.1600B
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 522.2483
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QR01AD11
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
NDF-RT |
N0000175450
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07AB09
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
A01AC01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.2483
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07XB02
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
R01AD11
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
H02AB08
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
NDF-RT |
N0000175576
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.2482
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07CB01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 524.1600A
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07BB03
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QD07XB02
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
S02CA04
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QC05AA12
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
CFR |
21 CFR 520.2483
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QR03BA06
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07CB01
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QS01BA05
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-VATC |
QS02CA04
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
S01BA05
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
C05AA12
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
||
|
WHO-ATC |
D07AB09
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C901
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
2725
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
100000092178
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
755
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
TRIAMCINOLONE
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
Triamcinolone, Topical
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
DB00620
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
124-94-7
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
m11027
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
2870
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
SUB11251MIG
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL1451
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
1676000
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
9667
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
Triamcinolone
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
10759
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
13397
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
31307
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
DTXSID1040742
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
3194
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
204-718-7
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY | |||
|
D014221
Created by
admin on Mon Mar 31 21:26:21 GMT 2025 , Edited by admin on Mon Mar 31 21:26:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|